About this trial
Evaluation of the Safety and Effectiveness of the Peripheral Embolization Coil System Manufactured by Suzhou Zhongtian Medical Instruments Co., Ltd. for the Treatment of Arteriovenous Embolization in the Peripheral Vasculature in a Real-World Setting
Eligibility criteria
Qualifiers
Aged 18 to 75 years (inclusive), regardless of gender;
Patients diagnosed preoperatively via imaging (including but not limited to ultrasound, CTA, MRA, DSA, etc.) with peripheral arteriovenous conditions requiring embolization therapy;
The visually estimated normal reference diameter of the target vessel is ≥ 3mm;
Patients or their legally authorized representatives are capable of understanding the study objectives, voluntarily participating in this study, providing signed informed consent, and able to comply with follow-up.
Disqualifiers
The target vessel requires the concurrent use of other embolic materials (e.g., Gelfoam, embolic microspheres, liquid embolic agents, etc.);
Known definite history of allergy to platinum, tungsten metals, and/or any component of the investigational product;
Subjects with pre-existing severe cardiac, hepatic, renal, respiratory diseases, or coagulation disorders who are unsuitable for anesthesia or endovascular surgical treatment;
High-flow arteriovenous fistulas that may cause migration of the embolic material;
Trial design
Treatments tested in this trial
- Peripheral Embolization Coil System
Treatment groups
Locations
Sponsors and collaborators
Suzhou Zenith Vascular Scitech Co., Ltd.
Lead sponsor
The First Affiliated Hospital of Soochow University
Collaborator